Brookfield Asset Management Inc. Biogen Inc. Transaction History

Brookfield Asset Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	SELL	$275.25 - $318.06 $1.93 Million - $2.23 Million	-7,022 Reduced 21.07%	26,305 $7.49 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $1.93 Million - $2.23 Million	-7,022 Reduced 21.07%	26,305 $7.49 Million
Q1 2023 Sep 25, 2023	BUY	$256.56 - $292.34 $1.8 Million - $2.05 Million	7,022 Added 26.69%	33,327 $9.27 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $3.07 Million - $3.49 Million	11,947 Added 55.88%	33,327 $9.27 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $1.28 Million - $1.55 Million	-5,066 Reduced 19.16%	21,380 $5.92 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $5.15 Million - $7.1 Million	26,446 New	26,446 $7.06 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $2.09 Million - $2.63 Million	10,763 Added 269.08%	14,763 $3.11 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $288,856 - $371,223	1,290 Added 47.6%	4,000 $959,000
Q3 2021 Nov 16, 2021	BUY	$282.99 - $369.05 $233,466 - $304,466	825 Added 43.77%	2,710 $766,000
Q2 2021 Aug 17, 2021	BUY	$259.0 - $414.71 $488,215 - $781,728	1,885 New	1,885 $652,000

1,032

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.